Summary of the 2018 Kidney Disease Improving Global Outcomes (KDIGO) Guideline on hepatitis C in chronic kidney disease

Abstract

KDIGO recently updated its clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD). The management of HCV in patients with CKD has dramatically shifted over the past 10 years with the development of direct-acting antiviral (DAA) agents and subsequent demonstration of their efficacy in CKD populations. The opportunity to cure HCV with DAA treatment has impacted all aspects of the KDIGO guideline on HCV in CKD including: (a) HCV diagnosis in CKD populations; (b) HCV treatment in CKD populations; (c) preventing HCV transmission in HD units; (d) management of HCV before and after kidney transplantation; and (e) management of HCV-associated glomerular disease. This review summarizes and discusses the major recommendations, along with the implication of the guideline on clinical practice.

Poor management of hepatitis C infection will cause serious issues for patients with advanced chronic kidney disease

“…After successful treatment for HCV there is no need for using separate HD machines. 6 HCV is ribonucleic acid (RNA) virus from the flaviviridae family. 5,7 There are six genotypes of the virus with its geographic distribution.…”

The Landscape and Prognosis Potential of the T-Cell Repertoire in Membranous Nephropathy

“…The laboratory assessment included APLA2R status, serum albumin, proteinuria, 24-h urine protein (24 hUP), urea nitrogen, creatinine, and eGFR levels, and these were collected at the time of renal biopsy and at 6-months follow-up. We evaluated the therapeutic effects of the patients according to KIDNEY DISEASE IMPROVING GLOBAL OUTCOMES (KDIGO) (21,22). We also recruited 19 healthy volunteers without a history of cancer, autoimmune disorder, or surgery as a control, and blood samples were drawn from each healthy volunteer.…”

Viral hepatitis in patients on hemodialysis

“…Hepatitis C virus treatment is recommended in all chronically infected individuals, regardless of level of viremia stage of liver fibrosis 78 . HCV is identified as an independent risk factor for both CKD onset and progression of CKD 77 .…”